What’s the Average Weight Loss on Mounjaro?

Last reviewed: July 15, 2026

Last updated: July 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, produced an average weight loss of 21% of total body weight in landmark clinical trials—significantly higher than traditional weight loss medications. However, actual results depend on your genetics, starting weight, dose tolerance, and commitment to lifestyle changes. PlexusDx offers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan to help you achieve personalized weight loss outcomes.

Clinical Trial Results for Tirzepatide Weight Loss

The SURMOUNT clinical trial program evaluated tirzepatide's effectiveness across three phases involving over 4,500 participants. In SURMOUNT-1, patients receiving the highest dose lost an average of 21% of their baseline body weight by week 68, compared to 3% in the placebo group. For context, a person weighing 250 pounds could expect to lose approximately 52 pounds on the active medication versus 7 pounds on placebo.

SURMOUNT-2 focused on participants with type 2 diabetes and demonstrated similar weight reduction patterns, with some patients achieving up to 23% body weight loss. These trials used titrated dosing schedules starting at the lowest dose and increasing gradually to maximize tolerability. The sustained results persisted through the 52-week maintenance phase, indicating that continued medication use maintains weight loss rather than temporary fluctuation.

Why Individual Weight Loss Varies on Tirzepatide

Not everyone loses exactly 21% of their body weight—some lose more, others less. Your genetic blueprint plays a significant role in how your body responds to GLP-1 and GIP receptor activation. The Precision Peptide Genetic Test from PlexusDx analyzes key variants including GLP1R rs6923761 and GIPR rs1800437 that influence how efficiently your digestive system signals fullness and regulates appetite hormones.

Starting body weight, metabolic rate, baseline insulin resistance, and medication adherence also shape outcomes. A person beginning treatment at 350 pounds may experience faster initial weight loss than someone starting at 200 pounds. Consistency matters too—patients who maintain steady dosing and combine medication with modest dietary adjustments typically outperform those who skip doses or rely solely on the injection without behavioral support.

Realistic First-Month and Long-Term Weight Loss Expectations

Most patients notice appetite suppression within days to weeks, but substantial weight loss typically becomes measurable by week 4 to 6 of consistent use. Early weight reduction often ranges from 5 to 15 pounds in the first month, driven by reduced calorie intake as hunger signals decrease. This initial phase provides motivation and proof-of-concept that the medication is working for your individual system.

Long-term weight loss continues over 12 to 16 weeks as doses increase and your body adapts to the medication. By month four to five, many patients report cumulative weight loss between 15 and 30 pounds depending on their starting point and dose level. The key is maintaining the same monthly price—PlexusDx keeps compounded tirzepatide injection at $289/mo (or $249/mo on the 6-month plan) flat, so your dose may increase as clinically needed without your price changing.

How PlexusDx Tirzepatide Compares to Brand-Name Mounjaro

PlexusDx provides compounded tirzepatide from licensed 503A compounding pharmacies containing the identical active pharmaceutical ingredient as brand Mounjaro, but at a significantly lower cost. The compounding process allows for precise customization of strength and format while maintaining pharmaceutical quality standards. Clinical effectiveness remains equivalent because the active compound—tirzepatide—is the same; the difference lies in pricing and accessibility without insurance requirements.

PlexusDx serves all 50 states and accepts HSA/FSA funds, removing insurance barriers that delay or prevent access to this high-efficacy medication. Starting at $249/mo for compounded tirzepatide injection, you receive a month's supply of medication with the same weight loss potential as brand Mounjaro costing $500+ per month through traditional pharmacies. Many patients combine the injection with PlexusDx's optional Precision Peptide Genetic Test ($99 add-on after first month) to understand their individual peptide-pathway response and optimize their treatment plan.

Maintaining Weight Loss After Reaching Your Goal

Clinical data demonstrates that weight loss is maintained while taking tirzepatide, but cessation of the medication may lead to gradual weight regain. The SURMOUNT trials did not measure long-term outcomes beyond discontinuation, so the exact trajectory of weight return remains individual-dependent. Many patients transition to maintenance dosing—a lower, effective dose that sustains weight loss with fewer potential side effects—rather than stopping entirely.

PlexusDx supports long-term tirzepatide therapy with ongoing clinical monitoring, dose adjustments, and lifestyle counseling integrated into your treatment plan. Your dose may need to go up or down over time, and your price remains flat at $249/mo, allowing budget predictability for sustained weight management. When combined with consistent dietary habits, physical activity, and stress management, compounded tirzepatide provides a durable foundation for lasting weight loss.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose in the first 3 months on tirzepatide?

Most patients lose between 10 and 25 pounds in the first three months as doses gradually increase. Results depend on your starting weight, initial tolerance to the medication, and dietary adherence. PlexusDx monitors your progress monthly and adjusts your compounded tirzepatide dose to maximize safety and efficacy.

Is 21% body weight loss guaranteed if I use tirzepatide?

The 21% figure represents the average across clinical trial participants, not a guarantee for any individual. Some patients lose more, others achieve 10-15% weight loss. Your genetic variations, metabolism, and lifestyle factors influence your personal outcome, which is why PlexusDx offers the Precision Peptide Genetic Test to identify your individual response pathways.

How does compounded tirzepatide from PlexusDx produce the same weight loss as brand Mounjaro?

Compounded tirzepatide contains the identical active pharmaceutical ingredient as Mounjaro, manufactured by licensed 503A compounding pharmacies under strict quality standards. The weight loss results are equivalent because the medication itself is the same; PlexusDx simply offers it at lower cost at $289/mo month-to-month, or from $249/mo on the 6-month plan without requiring insurance.

What happens to weight loss if I stop taking tirzepatide?

Clinical trials show weight loss is maintained while taking the medication, but cessation typically leads to gradual weight regain over months. Most patients benefit from continuing tirzepatide long-term at a maintenance dose to sustain results, which PlexusDx supports with stable monthly pricing and ongoing clinical guidance.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Average Weight Loss On Ozempic
• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.